1
|
Liu P, Wang S, Wang G, Zhao M, Du F, Li K, Wang L, Wu H, Chen J, Yang Y, Su G. Macrophage-derived exosomal miR-4532 promotes endothelial cells injury by targeting SP1 and NF-κB P65 signalling activation. J Cell Mol Med 2022; 26:5165-5180. [PMID: 36071548 PMCID: PMC9575109 DOI: 10.1111/jcmm.17541] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 08/01/2022] [Accepted: 08/26/2022] [Indexed: 11/27/2022] Open
Abstract
Atherosclerosis is a complex pathological process involving macrophages, endothelial cells and vascular smooth muscle cells that can lead to ischemic heart disease; however, the mechanisms underlying cell‐to‐cell communication in atherosclerosis are poorly understood. In this study, we focused on the role of exosomal miRNAs in crosstalk between macrophages and endothelial cells and explored the rarely studied molecular mechanisms involved. Our in vitro result showed that macrophage‐derived exosomal miR‐4532 significantly disrupted human umbilical vein endothelial cells (HUVECs) function by targeting SP1 and downstream NF‐κB P65 activation. In turn, increased endothelin‐1 (ET‐1), intercellular cell adhesion molecule‐1 (ICAM‐1) and vascular cell adhesion molecule‐1 (VCAM‐1) and decreased endothelial nitric oxide synthase (eNOS) expression in HUVECs increased attraction of macrophages, exacerbating foam cell formation and transfer of exosomal miR‐4532 to HUVECs. MiR‐4532 overexpression significantly promoted endothelial injury and pretreatment with an inhibitor of miR‐4532 or GW4869 (exosome inhibitor) could reverse this injury. In conclusion, our data reveal that exosomes have a critical role in crosstalk between HUVECs and macrophages. Further, exosomal miR‐4532 transferred from macrophages to HUVECs and targeting specificity protein 1 (SP1) may be a novel therapeutic target in patients with atherosclerosis.
Collapse
Affiliation(s)
- Peng Liu
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Shuya Wang
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Guangxin Wang
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Mingming Zhao
- Research Center of Translational Medicine, Jinan Central Hospital, Cheeloo College Shandong University, Jinan, Shandong, China
| | - Fengli Du
- Shandong Provincial Public Health Clinical Center, Jinan, Shandong, China
| | - Kaiyuan Li
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Lei Wang
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Huihui Wu
- Research Center of Translational Medicine, Jinan Central Hospital, Cheeloo College Shandong University, Jinan, Shandong, China
| | - Jiamin Chen
- Research Center of Translational Medicine, Jinan Central Hospital, Cheeloo College Shandong University, Jinan, Shandong, China
| | - Yang Yang
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Guohai Su
- Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| |
Collapse
|